文献速递白血病淋巴瘤

抗CD7同种异体WU-CART-007治疗复发/难治性T细胞恶性肿瘤的1/2期试验

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
PubMed 文献 · Blood · 2025-01-01

这项1/2期研究采用3+3剂量递增设计并在复发/难治性T细胞急性淋巴细胞白血病(T-ALL)/淋巴瘤(LBL)中扩展队列,评估抗CD7同种异体WU-CART-007。28例入组患者中13例接受推荐2期剂量(RP2D)900×10^6个细胞联合增强淋巴清除;RP2D下11例可评估患者总缓解率90.9%、复合完全缓解率72.7%。

要点

  • 最常见治疗相关不良事件为细胞因子释放综合征,发生率88.5%,其中3-4级占19.2%。
  • RP2D为900×10^6个WU-CART-007细胞联合增强淋巴清除化疗。
  • RP2D可评估的11例中总缓解率90.9%,复合完全缓解率72.7%。

核心结论

  • WU-CART-007在RP2D下对复发/难治性T-ALL/LBL显示出高缓解率,并有可能提供新的治疗选择。

研究设计与样本

  • 1/2期研究,采用3+3剂量递增设计,随后在复发/难治性T-ALL/LBL中进行队列扩展。
  • 28例患者入组,其中13例接受RP2D 900×10^6个WU-CART-007细胞联合增强淋巴清除化疗。
  • 患者在接受标准或增强淋巴清除化疗后接受1次WU-CART-007输注。
  • 主要目标为表征安全性和评估复合完全缓解率,均已达到。
  • 试验注册号为NCT04984356。

主要发现

  • 最常见治疗相关不良事件为细胞因子释放综合征,发生率88.5%,其中3-4级占19.2%。
  • 观察到2例1级免疫效应细胞相关神经毒性综合征事件(7.7%)和1例2级急性移植物抗宿主病事件(3.8%)。
  • 观察到1例2级免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征。
  • RP2D下接受增强淋巴清除化疗且可评估疗效的11例患者中,总缓解率为90.9%,复合完全缓解率为72.7%。

关键数值与推荐

  • 推荐2期剂量(RP2D)为900×10^6个WU-CART-007细胞联合增强淋巴清除化疗。
  • RP2D下可评估疗效的11例患者中,总缓解率90.9%,复合完全缓解率72.7%。
  • 细胞因子释放综合征发生率88.5%,其中3-4级占19.2%。
  • 免疫效应细胞相关神经毒性综合征事件2例(7.7%),均为1级。
  • 急性移植物抗宿主病事件1例(3.8%),为2级。

临床怎么用

  • 原文结论认为WU-CART-007在RP2D下对复发/难治性T-ALL/LBL显示出高缓解率,并有可能提供新的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T-cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3+3 dose-escalation design followed by cohort expansion in relapsed/refractory T-ALL/LBL. Patients received 1 infusion of WU-CART-007 after standard or enhanced lymphodepleting chemotherapy. The primary objectives, to characterize safety and assess the composite complete remission rate, were met. Of 28 patients enrolled, 13 received the recommended phase 2 dose (RP2D) of 900 × 106 cells of WU-CART-007 with enhanced lymphodepletion. The most common treatment-related adverse event was cytokine release syndrome (88.5%; 19.2% grade 3-4). Two grade 1 immune effector cell-associated neurotoxicity syndrome events (7.7%) and 1 grade 2 acute graft-versus-host disease event occurred (3.8%). One grade 2 immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome was observed. Among the 11 patients evaluable for response at the RP2D who received enhanced lymphodepleting chemotherapy, the overall response rate was 90.9%, and the composite complete remission rate was 72.7%. WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. This trial was registered at www.ClinicalTrials.gov as #NCT04984356.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghobadi A, Aldoss I, Maude SL, et al. Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Blood. 2025. PMID: 40445850. doi:10.1182/blood.2025028387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。